SingletO2 Therapeutics develops new treatments for periodontal disease using singlet oxygen.
SingletO2 Therapeutics has raised $75K in total funding. The most recent round was Grant. The last funding was announced in October 2024.
SingletO2 Therapeutics's investors include National Science Foundation, Commission on Science, Innovation and Technology.
SingletO2 Therapeutics is headquartered in New Providence, United States.
SingletO2 Therapeutics develops new treatments for periodontal disease using singlet oxygen.
SingletO2 Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SingletO2 Therapeutics — Funding & Investors." VCBacked, October 15, 2024, https://www.vcbacked.co/company/singleto2-therapeutics. Accessed August 18, 2026.
VCBacked. (2024). SingletO2 Therapeutics — Funding & Investors. Retrieved August 18, 2026, from https://www.vcbacked.co/company/singleto2-therapeutics
{{cite web |title=SingletO2 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/singleto2-therapeutics |website=VCBacked |access-date=August 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated